Shionogi

Shionogi Inc. is a U.S.-based subsidiary of the Japanese pharmaceutical company Shionogi & Co., Ltd., which has been a leader in drug development since its founding in 1878. The company focuses on creating innovative treatments for infectious diseases, pain management, HIV, and influenza. Notable products include antibiotics like sulfamethoxazole and Delafloxacin, which received FDA approval in 2017. With a strong commitment to research and development, Shionogi allocates over 15% of its annual revenue to R&D, driving advancements in various therapeutic areas. The company has established significant partnerships with major pharmaceutical firms, enhancing its global presence and ability to serve healthcare providers and patients worldwide. As of March 2023, Shionogi reported a revenue of approximately ¥420 billion (around $3.5 billion), reflecting its ongoing growth in the pharmaceutical market.